Located in the heart of the University's medical complex, the Small Animal Cancer Imaging Core provides intellectual and physical resources devoted to magnetic resonance imaging (MRI), positron emission tomography, (PET), and optical tomography (OT) directed toward small laboratory animals such as hamsters, rats and mice. MRI resources include a high-field 11.7 tesla multinuclear scanner, one of only a few worldwide, and three 4.7 tesia multinuclear scanners. Recent upgrades of electronics consoles, gradient coils, and gradient power supplies, have restored these instruments to state-of-the-art quality. The PET/CT Component is centered on two microPET scanners from Siemens Medical, including a newly acquired, state-of-the-art Inveon microPET-CT instrument. Two cyclotrons and an associated radiochemistry laboratory are connected to the PET facility via a pneumatic tube system and a small-bore gas line for transport of liquid (contained in syringes) and gaseous radiopharmaceuticals. Both MRI and PET scanners offer sensitivity and resolution optimized for small-animal research. Additional resources for support of small-animal imaging include housing, physiologic support and monitoring equipment, surgical procedure rooms, wet chemistry laboratories, and data analysis and archival systems. The Core provides Siteman Cancer Center members with the latest in small-animal MRI, PET, and OT capabilities. Highly skilled staff members are available to assist, advise, and collaborate on projects of interest to Siteman members. For the last five years, the Small Animal Cancer Imaging Core has been supported primarily through the National Cancer Institute (NCI) Small Animal Imaging Resource Program (SAIRP). Washington University Small Animal Imaging Resource (WUSAIR) was one of the original five SAIRP centers, established in 1999, and received ~$3 million in total support from 2004 to 2009.
MRI and PET are widely employed in the clinic;thus, new MR and PET imaging technology developed in the Small Animal Imaging Core can be seamlessly and immediately translated to the clinic for the direct benefit of cancer patients. In addition, the Core provides imaging platforms for pre-clinical development and assessment of new therapies for cancer treatment.
|Eberth, Jan M; Josey, Michele J; Mobley, Lee R et al. (2017) Who Performs Colonoscopy? Workforce Trends Over Space and Time. J Rural Health :|
|Kuroki, Lindsay M; Frolova, Antonina I; Wu, Ningying et al. (2017) Yield of Cytology Surveillance After High-Grade Vulvar Intraepithelial Neoplasia or Cancer. J Low Genit Tract Dis 21:193-197|
|Spencer, David H; Russler-Germain, David A; Ketkar, Shamika et al. (2017) CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression. Cell 168:801-816.e13|
|Cusworth, Brian M; Krasnick, Bradley A; Nywening, Timothy M et al. (2017) Whipple-specific complications result in prolonged length of stay not accounted for in ACS-NSQIP Surgical Risk Calculator. HPB (Oxford) 19:147-153|
|Wang, Xuya; Mooradian, Arshag D; Erdmann-Gilmore, Petra et al. (2017) Breast tumors educate the proteome of stromal tissue in an individualized but coordinated manner. Sci Signal 10:|
|Knoop, Kathryn A; Gustafsson, Jenny K; McDonald, Keely G et al. (2017) Microbial antigen encounter during a preweaning interval is critical for tolerance to gut bacteria. Sci Immunol 2:|
|Tang, Rui; Habimana-Griffin, LeMoyne M; Lane, Daniel D et al. (2017) Nanophotosensitive drugs for light-based cancer therapy: what does the future hold? Nanomedicine (Lond) 12:1101-1105|
|Song, Hao; Ruan, Dan; Liu, Wenyang et al. (2017) Respiratory motion prediction and prospective correction for free-breathing arterial spin-labeled perfusion MRI of the kidneys. Med Phys 44:962-973|
|Bandyopadhyay, Shovik; Li, Junjie; Traer, Elie et al. (2017) Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia. PLoS One 12:e0179558|
|Lim, Kian-Huat; Langley, Emma; Gao, Feng et al. (2017) A clinically feasible multiplex proteomic immunoassay as a novel functional diagnostic for pancreatic ductal adenocarcinoma. Oncotarget 8:24250-24261|
Showing the most recent 10 out of 1109 publications